SCM and Allele: iPSC-based Diabetes Drug Development
SCM Lifescience to in-license iPSCs-based diabetes drug from U.S. firm – Pulse by Maeil Business News Korea July 02, 2021, Seoul SCM Lifescience has agreed to in-license a diabetes drug using pancreatic beta cells derived from induced pluripotent stem cells (iPSCs) from San Diego-based Allele Biotechnology and Pharmaceuticals, the South Korean stem cell therapy developer…